Welcom to Sichuan Hengkang Science and Technology Development Co.,Ltd.

On January 17,2022, focusing on the use of artificial intelligence driven drug development announced, use its independent research and development of integrated AI new drug discovery platform Molecule Pro, in 8 months to design, verified 69 new small molecules and obtained for a class B G protein-coupled receptor (Class B GPCR) target preclinical candidates, the research pipeline has entered the IND-Enabling Studies stage. Historically, the development of Class B GPCR small-molecule agonists has proven very challenging.

auxiliary

The company used Molecule Pro platform design and virtual screening to predict several series of new skeleton structural molecules, some of which the new skeletal molecules reached the picimolar level after in vitro efficacy activity test. Through further in vitro mechanisms and pharmacogenic screening, in vivo efficacy / pharmacogenesis evaluation of large and small animals, and preliminary safety testing, the final nominated preclinical candidates showed similar optimal potential for efficacy, pharmacogenesis, and safety (for the unmet clinical needs of several large chronic diseases). 

Molecule Pro platform is especially good at solving the problem of multi-objective optimization in drug research and development, its independent research and development and integration of artificial intelligence model covers compound design, screening and optimization, novelty, synthesability, drug formation and toxicity prediction such as preclinical drug development key link, the development of drug target provides leapfrog acceleration, improve the success rate of platform solution. 

Molecule Pro platform is especially good at solving the problem of multi-objective optimization in drug research and development, its independent research and development and integration of artificial intelligence model covers compound design, screening and optimization, novelty, synthesability, drug formation and toxicity prediction such as preclinical drug development key link, the development of drug target provides leapfrog acceleration, improve the success rate of platform solution.


Post time: Jan-19-2022